Art Cain, a member of the PHEN Survivor Network from Atlanta, Georgia, shared his life-changing experience participating in the PANTHER clinical trial. Diagnosed with prostate cancer in 2015 and experiencing a recurrence in 2019, Cain's journey led him to the PANTHER trial through a fortuitous meeting with Dr. Daniel George from the Duke Cancer Institute at PHEN's 2019 Annual African American Prostate Cancer Disparity Summit in Washington, D.C.
"After talking with Dr. George and the folks at Duke, I decided to enter the PANTHER clinical trial," Art explained. Entering the trial at the end of 2019 with a PSA recurrence of about 6, his level became undetectable after a year in the trial, a status he maintains today, highlighting the life-saving potential of this trial.
Art Cain's experience clearly illustrates that prostate cancer patients diagnosed with advanced disease must understand that there is hope with treatment through prostate cancer clinical trials. The PANTHER clinical trial focused on a combination drug therapy consisting of apalutamide and abiraterone acetate plus prednisone. This regimen was shown to benefit Black men more significantly than White men.
|